Kyle Faget Authors Article on ‘Compliance Considerations for Entities Providing Hybrid Clinical Trial Services’
April 28, 2022
Journal of Health Care Compliance
Foley & Lardner LLP Partner Kyle Faget authored the article, “Compliance Considerations for Entities Providing Hybrid Clinical Trial Services,” for the March-April 2022 issue of the Journal of Health Care Compliance. In the article, she discusses how clinical trials are leveraging telehealth, the new business model of hybrid clinical trial services, and compliance considerations that should be addressed to enter the market safely.
Related News
May 1, 2026
In the News
David Rosen Weighs in on SCOTUS Review of Skinny Label Patent Dispute
Foley & Lardner LLP partner David Rosen is featured across the media for his perspective on the U.S. Supreme Court case Hikma Pharmaceuticals v. Amarin Pharma.
April 27, 2026
In the News
Jesse Neil Featured as a Distinguished Leader in Law.com's Southeastern Legal Awards
Foley & Lardner LLP partner Jesse Neil is recognized in Law.com as one of the Distinguished Leader honorees for the 2026 Southeastern Legal Awards.
April 27, 2026
In the News
David Rosen and William Holtz Analyze FDA Approval Speed, Biotech Pressures
Foley & Lardner LLP attorneys David Rosen and William Holtz are quoted in the PharmaVoice article, “FDA’s need for speed could strain small biotechs. Here’s how they can keep up,” examining the FDA’s accelerated drug approval initiatives and its impact on smaller pharmaceutical companies.